The company's cash runway of $22M is expected to fund operations through the IND and Phase 1a trial, but does not assume milestone warrant proceeds. Monitor for any milestone warrant exercises and the IND submission timeline in H1 2027.
Price Chart
How similar events traded
Executive Summary
Azora Therapeutics (formerly Adial Pharmaceuticals) reported a net loss of $64.6M for Q3 2026, primarily driven by a $57.1M non-cash charge from the change in fair value of milestone warrant rights. The company ended the quarter with $22.0M in cash, which it expects to fund operations through the planned IND submission and Phase 1a trial for AT177 in H1 2027. The business update also highlighted the name change, new Nasdaq ticker (AZR), and appointment of a new executive team and board.
Key Financial Metrics
Key Facts
- Net loss of $64.6M ($4.52 per share) for Q3 2026, including a $57.1M non-cash charge for change in fair value of milestone warrant rights liability.
- Cash and cash equivalents of $22.0M as of September 30, 2026, down from $28.7M at June 30, 2026.
- R&D expenses increased to $1.8M (from $0.5M in Q3 2025) due to preclinical and toxicology work for AT177.
- G&A expenses rose to $5.8M (from $1.2M in Q3 2025) due to merger and integration costs, stock-based compensation, and severance.
- Company changed name from Adial Pharmaceuticals to Azora Therapeutics and began trading under ticker AZR on October 29, 2026.
- New executive team appointed: Matt Davidson (CEO), Celia Economides (CFO), Julie Saiki (CSO), David Rubenstein (Chief Scientist).
- Up to $32.4M in gross proceeds could be received if investors elect to purchase milestone warrants.
- IND submission and Phase 1a trial for AT177 (oral AhR agonist for ulcerative colitis) planned for H1 2027.
Financial Impact
Net loss of $64.6M in Q3 2026 vs $1.8M in Q3 2025; cash burn of $6.7M from June 30 to September 30, 2026.
Risk Factors
- Stockholders' deficit of $21.1M as of September 30, 2026, though expected to be resolved by Series A preferred stock conversion in Q4 2026.
- No revenue; pre-commercial stage biotech with significant ongoing cash burn.
- Dependence on successful IND submission and Phase 1a trial for AT177 in H1 2027.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402168 |
Track record
23 reports on ADIL
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +138.93% at T+60 after the Jun 11, 2026 report. 5 of 10 went positive at some point.
Filters
- Nov 12, 20265d ago Press Release Neutral 4/10 Viewing No price data
- Oct 30, 202617d ago 3 Neutral 2/10 Entry $3.89 settles Jan 29
- Oct 30, 202617d ago 3 Neutral 2/10 Entry $3.89 settles Jan 29
- Oct 28, 202620d ago 8-K Neutral 5/10 Entry $4.88 settles Jan 27
- Oct 28, 202620d ago Press Release Neutral 5/10 Entry $4.88 settles Jan 27
- Oct 27, 202621d ago EFFECT Bearish 6/10 Entry $3.71 settles Jan 25
- Oct 20, 202627d ago 10-Q/A Bearish 7/10 Entry $4.11 settles Jan 19
- Oct 20, 202627d ago S-3/A Bearish 7/10 Entry $4.11 settles Jan 19
- Oct 16, 20264w ago DEFA14A Bearish 5/10 Entry $3.62 settles Jan 14
- Oct 16, 20264w ago 8-K Bearish 5/10 Entry $3.62 settles Jan 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers